Home
About
Share This
Set as HomepageSerono
Cladribine Tablets FDA Submission FINAL US FINAL
News Release Contact: Heather Hatfield 781-681-2124 September 30, 2009 EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States Rockland, Massachusetts, September 30, 2009 - EMD Serono, Inc. an affiliate of Merck KGaA ...
EMD Serono, Inc. Committed to Transparency in Interactions ...
News Release Contact: Jennifer Bianco 781-681-2861 June 23, 2011 EMD Serono, Inc. Committed to Transparency in Interactions with Healthcare Professionals and Organizations • Company will disclose details about financial interactions with physicians and funding of healthcare related grants ...
Merck Serono Announces Initiation of the ORACLE MS Trial to ...
News Release September 18, 2008 Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis • ORACLE MS Phase III trial will assess effectiveness of cladribine tablets in preventing conversion to definite multiple ...
Merck Serono's Safinamide Significantly Improved Motor ...
News Release February 3, 2009 Merck Serono's Safinamide Significantly Improved Motor Function in Patients with Advanced Parkinson's Disease in a Phase III Pivotal Trial • The six-month primary efficacy endpoint of the study was met: both doses of investigational agent safinamide significantly ...
Merck Serono: European Commission Approves Erbitux for First ...
News Release December 1, 2008 Merck Serono: European Commission Approves Erbitux for First-Line Use in Head and Neck Cancer • Erbitux approved for first-line use in combination with platinum-based chemotherapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and ...
EMD Serono 401(k) Savings and Retirement Account Plan ...
ONE Company. ONE Retirement Program. Serono Version S 06 EMD Serono 401(k) Savings and Retirement Account Plan Frequently Asked Questions (FAQs) Here are answers to frequently asked questions (FAQs) about the new EMD Serono 401(k) Savings and Retirement Account Plan (the new Plan) and the ...
Merck Serono: Stimuvax Clinical Program Temporarily Suspended
News Release March 23, 2010 Merck Serono: Stimuvax Clinical Program Temporarily Suspended Geneva, Switzerland, March 23, 2010 - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has temporarily suspended the clinical program for Stimuvax ® (BLP25 liposome ...
Review - Interferon alfa-1a, (Rebif) Serono, Incorporated
DEPARTMENT OF HEALTH & HUMAN SERVICES P UBLIC H EALTH S ERVICE Food and Drug Administration Memorandum Center for Biologics Evaluation and Research 1401 Rockville Pike Rockville, MD 20852 Division of Clinical Trial Design and Analysis HFM-576 Date: March 7, 2002 From: C. Rask, E. Unger, M ...
Merck Serono International S.A. Fast Facts - One Synchronized ...
Merck Serono International S.A. Fast Facts Industry Pharmaceuticals and Biopharmaceuticals Manufacturer Headquarters Geneva, Switzerland Description
Serono Settlement Should Highlight Need for Compliance, Not ...
Food and Drug Series December.2005.|.Vol..13,.No..10 With permission from Thompson, www.thompson.com Serono Settlement Should Highlight Need for Compliance, Not Chill
